We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Valneva SE (VLA) Common Shares EUR0.15

Sell:€3.08 Buy:€3.08 Change: €0.077 (2.44%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: €0.077 (2.44%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: €0.077 (2.44%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Contact details

6 rue Alain Bombard
+33 (2) 28073710

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€438.22 million
Shares in issue:
138.77 million
Euronext Paris

Key personnel

  • Thomas Lingelbach
    President, Chief Executive Officer, Director
  • Peter Buhler
    Chief Financial Officer
  • Vincent Dequenne
    Chief Operating Officer
  • Frederic Jacotot
    General Counsel, Company Secretary
  • Franck Grimaud
    Chief Business Officer
  • Juan Jaramillo
    Chief Medical Officer
  • Dipal Patel
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.